Halozyme Therapeutics (HALO) EBT Margin (2010 - 2026)
Halozyme Therapeutics (HALO) reported EBT Margin of 47.87% for Q1 2026, down 643.0% year-over-year from 8.82% in Q1 2025, and up 314.44% quarter-over-quarter from 22.32% in Q4 2025.
Halozyme Therapeutics (HALO) EBT Margin (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has 17 years of EBT Margin data on file, last reported at 47.87% in Q1 2026.
- EBT Margin for Q1 2026 came in at 47.87%, down 643.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 33.37% (down 2242.0% YoY), and the FY2025 annual result was 33.43%, down 2144.0% from the prior year.
- EBT Margin improved to 47.87% in Q1 2026 per HALO's latest filing, from 22.32% in the prior quarter.
- Over five years, EBT Margin peaked at 63.45% in Q1 2022 and troughed at 22.32% in Q4 2025.
- A 5-year average of 43.77% and a median of 47.87% in 2026 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2025: EBT Margin soared 3190 bps in 2022, then slumped 8212 bps in 2025.
- A 5-year view of EBT Margin shows it stood at 39.0% in 2022, then advanced by 13 bps to 43.98% in 2023, then soared by 36 bps to 59.8% in 2024, then plunged by 137 bps to 22.32% in 2025, then jumped by 314 bps to 47.87% in 2026.
- Business Quant data shows HALO's EBT Margin at 47.87% in Q1 2026, 22.32% in Q4 2025, and 61.81% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 6.40% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Halozyme Therapeutics | 8.24 Bn | 7.92 Bn | 297.47 Mn | 47.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.87% |
| Dec 31, 2025 | -22.32% |
| Sep 30, 2025 | 61.81% |
| Jun 30, 2025 | 62.92% |
| Mar 31, 2025 | 54.30% |
| Dec 31, 2024 | 59.80% |
| Sep 30, 2024 | 56.93% |
| Jun 30, 2024 | 50.89% |
| Mar 31, 2024 | 49.02% |
| Dec 31, 2023 | 43.98% |
| Sep 30, 2023 | 47.10% |
| Jun 30, 2023 | 42.14% |
| Mar 31, 2023 | 32.22% |
| Dec 31, 2022 | 39.00% |
| Sep 30, 2022 | 35.27% |
| Jun 30, 2022 | 19.70% |
| Mar 31, 2022 | 63.45% |
| Dec 31, 2021 | 53.73% |
| Sep 30, 2021 | 63.98% |
| Jun 30, 2021 | 67.07% |